Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
TPS3A is a homogeneous polysaccharide isolated and purified from Tianzhu Xianyue fried green tea. Structurally, it is a high-molecular-weight complex (1.596 × 10^4 kDa) primarily composed of arabinose, galactose, galacturonic acid, and rhamnose in a molar ratio of 5.84: 4.15: 2.06: 1. In preclinical models of atherosclerosis using ApoE-deficient mice, TPS3A has demonstrated the ability to delay atherosclerotic plaque progression and modulate dyslipidemia. Its mechanism of action involves inhibiting the phenotypic transition of vascular smooth muscle cells (VSMCs) from a contractile to a synthetic state, specifically by upregulating the contractile marker alpha-smooth muscle actin (α-SMA) and downregulating the synthetic marker osteopontin (OPN).
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on TPS3A.